scholarly journals Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma

2005 ◽  
Vol 116 (4) ◽  
pp. 579-583 ◽  
Author(s):  
Gianluigi Giannelli ◽  
Felice Marinosci ◽  
Concetta Sgarra ◽  
Luigi Lupo ◽  
Pietro Dentico ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Serum Levels ◽  
Clinical Role

Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC)

2014 ◽  
Vol 29 (8) ◽  
pp. 1637-1644 ◽  
Author(s):  
Caterina Pozzan ◽  
Romilda Cardin ◽  
Marika Piciocchi ◽  
Nora Cazzagon ◽  
Gemma Maddalo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Serum Levels ◽  
Prognostic Role

scholarly journals The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosis

2016 ◽  
Vol 7 (4) ◽  
pp. 615-623 ◽  
Author(s):  
Masayoshi Yada ◽  
Masayuki Miyazaki ◽  
Kenta Motomura ◽  
Akihide Masumoto ◽  
Makoto Nakamuta ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lactate Dehydrogenase ◽  
Liver Fibrosis ◽  
Serum Levels ◽  
Prognostic Role

scholarly journals Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Luca Faloppi ◽  
Maristella Bianconi ◽  
Riccardo Memeo ◽  
Andrea Casadei Gardini ◽  
Riccardo Giampieri ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lactic Dehydrogenase ◽  
Serum Levels ◽  
Clinical Results ◽  
Significant Prognostic Factor ◽  
Hypoxic Conditions ◽  
Potential Biomarker ◽  
Key Enzyme ◽  
Primary Liver Tumour

Hepatocellular carcinoma (HCC) is the most common primary liver tumour (80–90%) and represents more than 5.7% of all cancers. Although in recent years the therapeutic options for these patients have increased, clinical results are yet unsatisfactory and the prognosis remains dismal. Clinical or molecular criteria allowing a more accurate selection of patients are in fact largely lacking. Lactic dehydrogenase (LDH) is a glycolytic key enzyme in the conversion of pyruvate to lactate under anaerobic conditions. In preclinical models, upregulation of LDH has been suggested to ensure both an efficient anaerobic/glycolytic metabolism and a reduced dependence on oxygen under hypoxic conditions in tumour cells. Data from several analyses on different tumour types seem to suggest that LDH levels may be a significant prognostic factor. The role of LDH in HCC has been investigated by different authors in heterogeneous populations of patients. It has been tested as a potential biomarker in retrospective, small, and nonfocused studies in patients undergoing surgery, transarterial chemoembolization (TACE), and systemic therapy. In the major part of these studies, high LDH serum levels seem to predict a poorer outcome. We have reviewed literature in this setting trying to resume basis for future studies validating the role of LDH in this disease.

Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma

2002 ◽  
Vol 97 (4) ◽  
pp. 425-431 ◽  
Author(s):  
Gianluigi Giannelli ◽  
Carlo Bergamini ◽  
Felice Marinosci ◽  
Emilia Fransvea ◽  
Michele Quaranta ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Role

scholarly journals Elevated Levels of IL-33, IL-17 and IL-25 Indicate the Progression from Chronicity to Hepatocellular Carcinoma in Hepatitis C Virus Patients

Pathogens ◽  
2022 ◽  
Vol 11 (1) ◽  
pp. 57
Author(s):  
Momen Askoura ◽  
Hisham A. Abbas ◽  
Hadeel AlSadoun ◽  
Wesam H. Abdulaal ◽  
Amr S. Abu Lila ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Viral Load ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Serum Level ◽  
Viral Infections ◽  
Serum Levels ◽  
Chronic Patients

Hepatitis C virus (HCV) is one of the most epidemic viral infections in the world. Three-quarters of individuals infected with HCV become chronic. As a consequence of persistent inflammation, a considerable percentage of chronic patients progress to liver fibrosis, cirrhosis, and finally hepatocellular carcinoma. Cytokines, which are particularly produced from T-helper cells, play a crucial role in immune protection against HCV and the progression of the disease as well. In this study, the role of interleukins IL-33, IL-17, and IL-25 in HCV patients and progression of disease from chronicity to hepatocellular carcinoma will be characterized in order to use them as biomarkers of disease progression. The serum levels of the tested interleukins were measured in patients suffering from chronic hepatitis C (CHC), hepatocellular carcinoma (HCC), and healthy controls (C), and their levels were correlated to the degree of liver fibrosis, liver fibrosis markers and viral load. In contrast to the IL-25 serum level, which increased in patients suffering from HCC only, the serum levels of both IL-33 and IL-17 increased significantly in those patients suffering from CHC and HCC. In addition, IL-33 serum level was found to increase by liver fibrosis progression and viral load, in contrast to both IL-17 and IL-25. Current results indicate a significant role of IL-33 in liver inflammation and fibrosis progress in CHC, whereas IL-17 and IL-25 may be used as biomarkers for the development of hepatocellular carcinoma.

scholarly journals Tryptase serum levels in patients suffering from hepatocellular carcinoma undergoing intra-arterial chemoembolization: Possible predictive role of response to treatment

2013 ◽  
Vol 1 (2) ◽  
pp. 385-389 ◽  
Author(s):  
VERONICA GOFFREDO ◽  
COSMO DAMIANO GADALETA ◽  
ANNAMARIA LATERZA ◽  
ANGELO VACCA ◽  
GIROLAMO RANIERI
Keyword(s):  
Hepatocellular Carcinoma ◽  
Serum Levels ◽  
Response To Treatment ◽  
Predictive Role ◽  
Arterial Chemoembolization

scholarly journals Serum levels of Vitamin D3, Zinc, and Parathyroid Hormone in HCV-induced Hepatocellular Carcinoma.

2021 ◽  
Author(s):  
Mahmoud Khattab ◽  
Mohammad Omar Abdelaziz ◽  
Arwa Mohamad ◽  
Ragaa Abd- Elshaheed Matta ◽  
Magdy Fouad ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Parathyroid Hormone ◽  
Vitamin D3 ◽  
Serum Levels ◽  
Cross Sectional ◽  
Multiple Stepwise Regression Analysis ◽  
The Metabolic Syndrome ◽  
Calcium And Phosphorus

Abstract Background and AimThe role of the metabolic syndrome in hepatocellular carcinoma (HCC) has been previously reported. This study aims to investigate the possible role of vitamin D3, Zinc, Parathyroid hormone (PTH), calcium and phosphorus serum levels as non-traditional metabolic risk factors in HCV-related HCC.MethodThis cross-sectional observational study recruited HCV infected patients with and without HCC. All patients were subjected to demographic, biochemical, and hematological assessment. Serum levels of vitamin D3, Zinc, PTH, calcium, and phosphorus were determined in all the study participants.ResultsThis study includes 50 patients with HCV-related HCC compared to 40 patients with HCV-related liver cirrhosis and 30 patients with HCV chronic hepatitis C (CHC) without HCC. Our results show significantly higher age, male sex, aspartate transaminase (AST), PTH and corrected serum calcium levels in the HCC patients compared to values in the other two groups, (p < 0.001); while significant lower vitamin D3 and zinc levels were detected among the HCC patients compared to patients with non-HCC liver cirrhosis and CHC, (p < 0.001).Vitamin D3 deficiency was detected in 96% of the HCC patients, while it was detected in only 22.5% of the cirrhotic patients and in none of the CHC patients, (p < 0.001). However, on multiple stepwise regression analysis, only the age, AST, PTH, and corrected calcium levels were the independent predictors for HCC when studied in relation to chronic liver disease.ConclusionThis study indicates the prevalent deficient levels of vitamin D3 and zinc in HCC patients; however, a causal relationship is not established in this study.

Homocysteine Serum Levels as Prognostic Marker of Hepatocellular Carcinoma with Portal Vein Thrombosis

2019 ◽  
Vol 19 (7) ◽  
pp. 532-538
Author(s):  
Saverio Latteri ◽  
Giulia Malaguarnera ◽  
Vito Emanuele Catania ◽  
Gaetano La Greca ◽  
Gaetano Bertino ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Serum Levels ◽  
High Serum ◽  
Thrombotic Risk ◽  
Mean Values ◽  
Vein Thrombosis ◽  
Thrombotic Risk Factor

Background: Portal vein thrombosis (PVT) is a common complication of endstage hepatocellular carcinoma (HCC). : The aim of our study was to evaluate the role of Homocysteine (Hcy) in HCC patient with PVT. Hcy is a sulphur amino-acid involved in two pathways, trans-sulphuration and remethylation, that involve vitamins B6, B12 and folates. Methods: We recruited 54 patients with HCC and PVT, 60 patients with HCC and without PVT and 60 control subjects. We measured serum levels of Hcy, folate, vitamins B6 and B12. Results: The comparison between HCC patients with PVT versus HCC without PVT was shown that mean values of Hcy were 6.4 nmol/L (p<0.0073) higher, LDL cholesterol were 4.8 mg/dl (p<0.0079) lower, vitamin B6 were 4.6 nmol/L(p=0.0544) lower, vitamins B 12 were 22.1 pg/ml (p=0.0001) lower. Conclusion: High serum levels of Hcy are an established thrombotic risk factor in the general population. We found significantly higher levels of Hcy in HCC patients with PVT versus both HCC patients without PVT and controls.

The role of chemokine CC ligand 20 in patients with liver cirrhosis and hepatocellular carcinoma

2012 ◽  
Vol 27 (2) ◽  
pp. 125-131 ◽  
Author(s):  
Hanan H. Soliman ◽  
Hala Nagy ◽  
Nesreen Kotb ◽  
Mohamed A. Alm El-Din
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Predictive Value ◽  
Serum Levels ◽  
Study Groups ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Asymptomatic Patients ◽  
Group I

Background and aim To evaluate the role of chemokine CC ligand 20 (CCL20) as a biomarker for hepatocellular carcinoma (HCC). Patients and methods Ninety patients in four groups were enrolled in this prospective cross-sectional study: 30 with HCC (group I), 30 with liver cirrhosis (group II), 15 with hepatitis C virus infection (group III), and 15 healthy blood donors as controls. Alpha fetoprotein (AFP), CCL20 and vascular endothelial growth factor (VEGF) were measured in all groups. Results Serum levels of CCL20 were significantly different among the study groups (F=230.979, p<0.001). The highest level was found in HCC patients (57.305 ± 6.386 pg/mL) followed by patients with cirrhosis (45.999 ± 5.165 pg/mL) compared with 22.781 ± 5.986 pg/mL and 18.585 ± 3.554 pg/mL in asymptomatic patients with HCV infection and controls, respectively. In HCC patients, CCL20 significantly correlated with VEGF (r=0.559, p=0.001), AFP (r=0.814, p<0.001), Child score (r=0.748, p<0.001), and tumor size (r=0.825, p<0.001). The cutoff value of CCL20 for the detection of HCC in HCV-infected patients was 54 pg/mL with 93.1% accuracy, 89.6% negative predictive value, 92.6% positive predictive value, 83.3% sensitivity, and 93.3% specificity. In patients with cirrhosis, CCL20 significantly correlated with VEGF (r=0.455, p=0.011), AFP (r=0.975, p<0.001), and Child score (r=0.977, p<0.001). Conclusion CCL20 may be used for the detection of HCC in HCV-infected patients with comparable specificity and higher sensitivity than AFP.

Sign in / Sign up

Export Citation Format

Share Document